HK1013997A1 - Pyridazino quinoline compounds - Google Patents

Pyridazino quinoline compounds

Info

Publication number
HK1013997A1
HK1013997A1 HK98115415A HK98115415A HK1013997A1 HK 1013997 A1 HK1013997 A1 HK 1013997A1 HK 98115415 A HK98115415 A HK 98115415A HK 98115415 A HK98115415 A HK 98115415A HK 1013997 A1 HK1013997 A1 HK 1013997A1
Authority
HK
Hong Kong
Prior art keywords
phenyl
deriv
substd
opt
furyl
Prior art date
Application number
HK98115415A
Other languages
English (en)
Inventor
Thomas Michael Bare
Richard Bruce Sparks
James Roy Empfield
Timothy Wayne Davenport
Jeffrey Alan Mckinney
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939321854A external-priority patent/GB9321854D0/en
Priority claimed from GB9417171A external-priority patent/GB9417171D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of HK1013997A1 publication Critical patent/HK1013997A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HK98115415A 1993-10-22 1998-12-24 Pyridazino quinoline compounds HK1013997A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939321854A GB9321854D0 (en) 1993-10-22 1993-10-22 Pyridazino quinoline compounds
GB9417171A GB9417171D0 (en) 1994-08-25 1994-08-25 Pyridazino quinoline compounds
PCT/GB1994/002295 WO1995011244A1 (en) 1993-10-22 1994-10-20 Pyridazino quinoline compounds

Publications (1)

Publication Number Publication Date
HK1013997A1 true HK1013997A1 (en) 1999-09-17

Family

ID=26303731

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98115415A HK1013997A1 (en) 1993-10-22 1998-12-24 Pyridazino quinoline compounds

Country Status (30)

Country Link
US (3) US5744471A (fi)
EP (2) EP1004582B1 (fi)
JP (1) JP3583132B2 (fi)
KR (1) KR100261209B1 (fi)
CN (1) CN1053189C (fi)
AT (2) ATE295846T1 (fi)
AU (2) AU688393B2 (fi)
CA (1) CA2171332A1 (fi)
CZ (1) CZ292311B6 (fi)
DE (2) DE69426422T2 (fi)
DK (2) DK0724583T3 (fi)
ES (2) ES2154686T3 (fi)
FI (2) FI113865B (fi)
GB (1) GB9420590D0 (fi)
GR (1) GR3035080T3 (fi)
HK (1) HK1013997A1 (fi)
HU (1) HUT74161A (fi)
IL (1) IL111266A (fi)
MY (2) MY132875A (fi)
NO (1) NO306995B1 (fi)
NZ (2) NZ329303A (fi)
PL (1) PL180679B1 (fi)
PT (2) PT724583E (fi)
RU (1) RU2168511C2 (fi)
SG (2) SG92630A1 (fi)
SI (2) SI0724583T1 (fi)
SK (1) SK282491B6 (fi)
TW (1) TW406082B (fi)
UA (1) UA60291C2 (fi)
WO (1) WO1995011244A1 (fi)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111266A (en) * 1993-10-22 2002-03-10 Zeneca Ltd 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6214826B1 (en) 1994-11-12 2001-04-10 Zeneca Limited Pyridazino quinoline compounds
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
AU2420101A (en) * 1999-12-23 2001-07-09 Astrazeneca Ab Method and composition for the treatment of pain
US6943165B2 (en) * 1999-12-23 2005-09-13 Astrazeneca Ab Compound and method for the treatment of pain
US6787547B2 (en) 1999-12-23 2004-09-07 Astrazeneca Ab Compound and method for the treatment of pain
IL150208A0 (en) * 1999-12-23 2002-12-01 Astrazeneca Ab Compound and method for the treatment of pain
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
US20050124622A1 (en) * 1999-12-23 2005-06-09 Brown Dean G. Compounds and methods for the treatment of pain
US6730675B2 (en) 1999-12-23 2004-05-04 Astrazeneca Ab Compounds and methods for the treatment of pain
WO2001047925A1 (en) * 1999-12-23 2001-07-05 Astrazeneca Ab Compounds and methods for the treatment of pain
EP1577311A1 (en) * 1999-12-23 2005-09-21 AstraZeneca AB Salts of a pyridazino aquinoline derivative and use for the treatment of pain
AU2420001A (en) * 1999-12-23 2001-07-09 Astrazeneca Ab Methods and compositions for the treatment of pain
JP2003519145A (ja) * 1999-12-23 2003-06-17 アストラゼネカ・アクチエボラーグ 痛みの処置のための化合物および方法
BR0016646A (pt) * 1999-12-23 2002-10-08 Astrazeneca Ab Método para tratar um paciente que sofre de dor, e, composição farmacêutica
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
US6833368B2 (en) 2000-09-29 2004-12-21 Astrazeneca Ab 1, 2, 5, 10-tetrahydropyridazino[4, 5-b]quinoline-1,10-diones and their use for the treatment of pain
EP1325005A1 (en) * 2000-09-29 2003-07-09 AstraZeneca AB 1,2,5,10-tetrahydropyridazino 4,5-b]quinoline-1,10-diones and their use for the treatment of pain
US6933297B2 (en) 2000-09-29 2005-08-23 Astrazeneca Ab 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione and the use thereof for the treatment of pain
AU2001292500A1 (en) * 2000-09-29 2002-04-08 Astrazeneca Ab 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
AU2002304358B2 (en) * 2001-05-31 2007-08-23 Sanofi-Aventis Aminoquinoline and aminopyridine derivatives and their use as adenosine A3 ligands
WO2005012309A1 (en) * 2003-08-04 2005-02-10 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
ES2656017T3 (es) 2004-06-24 2018-02-22 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de unión a ATP
JP2009521468A (ja) * 2005-12-24 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Abc輸送体の調節因子としてのキノリン−4−オン誘導体
PL1993360T3 (pl) 2005-12-28 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CA2865519C (en) 2012-02-27 2018-01-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109972D0 (en) * 1991-05-09 1991-07-03 Ici Plc Therapeutic compounds
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
IL111266A (en) * 1993-10-22 2002-03-10 Zeneca Ltd 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds

Also Published As

Publication number Publication date
NZ329303A (en) 2000-01-28
MY124316A (en) 2006-06-30
US6103721A (en) 2000-08-15
US6232313B1 (en) 2001-05-15
CZ292311B6 (cs) 2003-09-17
FI970907A (fi) 1997-03-03
CA2171332A1 (en) 1995-04-27
HUT74161A (en) 1996-11-28
SK282491B6 (sk) 2002-02-05
FI961696A0 (fi) 1996-04-18
NO961584D0 (no) 1996-04-19
UA60291C2 (uk) 2003-10-15
PL180679B1 (en) 2001-03-30
EP1004582A3 (en) 2000-08-30
FI114916B (fi) 2005-01-31
JP3583132B2 (ja) 2004-10-27
IL111266A (en) 2002-03-10
GB9420590D0 (en) 1994-11-30
US5744471A (en) 1998-04-28
PL314041A1 (en) 1996-08-05
CN1138332A (zh) 1996-12-18
DE69426422T2 (de) 2001-05-10
ATE198072T1 (de) 2000-12-15
SG92630A1 (en) 2002-11-19
EP1004582B1 (en) 2005-05-18
MY132875A (en) 2007-10-31
EP0724583A1 (en) 1996-08-07
ATE295846T1 (de) 2005-06-15
RU2168511C2 (ru) 2001-06-10
FI961696A (fi) 1996-04-18
WO1995011244A1 (en) 1995-04-27
FI970907A0 (fi) 1997-03-03
EP1004582A2 (en) 2000-05-31
NZ275472A (en) 1998-03-25
PT724583E (pt) 2001-03-30
FI113865B (fi) 2004-06-30
SG59971A1 (en) 1999-02-22
KR100261209B1 (ko) 2000-09-01
PT1004582E (pt) 2005-09-30
TW406082B (en) 2000-09-21
DE69434380D1 (de) 2005-06-23
AU721139B2 (en) 2000-06-22
EP0724583B1 (en) 2000-12-13
NO306995B1 (no) 2000-01-24
NO961584L (no) 1996-04-19
SI0724583T1 (en) 2001-04-30
ES2241513T3 (es) 2005-11-01
CN1053189C (zh) 2000-06-07
JPH09504519A (ja) 1997-05-06
HU9600889D0 (en) 1996-06-28
ES2154686T3 (es) 2001-04-16
DE69426422D1 (de) 2001-01-18
AU7944094A (en) 1995-05-08
DK0724583T3 (da) 2001-03-05
GR3035080T3 (en) 2001-03-30
DK1004582T3 (da) 2005-08-15
DE69434380T2 (de) 2006-05-04
SK50496A3 (en) 1997-03-05
IL111266A0 (en) 1994-12-29
AU688393B2 (en) 1998-03-12
CZ113896A3 (en) 1996-09-11
SI1004582T1 (fi) 2005-08-31
AU6899998A (en) 1998-07-30

Similar Documents

Publication Publication Date Title
GB9420590D0 (en) Pyridazino quinoline compounds
DE69428476T2 (de) Heterocyclische Verbindungen als Bradykinin Antagonisten
EA199900927A1 (ru) Трициклические соединения
ES8600288A1 (es) Un procedimiento para la preparacion de derivados de quinolina.
ATE148700T1 (de) Tricyclische heterocyclen als pge2-antagonisten
SE9904177D0 (sv) Novel compounds
DE69207182D1 (en) Antitumor anthracenderivate
DE69316392D1 (de) Azanoradamantane
ES2063177T3 (es) Antagonistas de calcio.
FR2342063A2 (fr) Nouveaux acetamidoximes, leur procede de preparation et leur application en therapeutique

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20091020